الفهرس 
CytokinesOnly 14 pages are availabe for public view
 |  | from | 211 |  |  |
| | | from | 211 | | |
Abstract
This study was aimed to measure the serum level of Anti‑ C1q and Anti-nucleosome Antibodies (anti-NCS) in SLE patients, and to evaluate the correlation between Anti‑ C1q and Anti-nucleosome (anti-NCS) regarding SLE disease activity. This study consisted of randomized sixty subjects divided into two groups: group I: included 30 SLE patients. group II (Control group): included 30 healthy volunteers. Serum anti-c1q and anti-nucleosome antibodies were statistically highly significant in SLE patients than normal control group, in active SLE than inactive, in SLE patients with nephritis than patients without nephritis and in the presence of SLE activity with nephritis than the absence of SLE activity and nephritis. Both anti-c1q and anti-nucleosome antibodies were positively correlated with SLEDAI and renal SLEDAI scores, but anti-c1q show stronger correlation with SLEDAI than anti-nucleosome. Both anti-c1q and anti-nucleosome antibodies had high sensitivity and specificity for diagnosis of SLE patients. Both anti-c1q and anti-nucleosome antibodies had high sensitivity and low specificity for diagnosis of SLE disease activity and renal flare. Anti-dsDNA antibodies did not have correlation with SLEDAI and renal SLEDAI scores. Anti-c1q antibodies show higher positivity than anti-nucleosome and anti-dsDNA antibodies among SLE patients and healthy control. Both anti-c1q and anti-nucleosome antibodies were associated with LN, although the association might be more with anti-nucleosome